Charles River Laboratories International, Inc (CRL)
Charles River Laboratories International, Inc. is a healthcare company listed on the NYSE as common stock. It provides drug discovery, non-clinical development, and safety testing services to pharmaceutical, biotechnology, and related life sciences clients in the United States, Europe, Canada, the Asia Pacific, and other international markets. The company operates through three main segments. Its Research Models and Services division supplies rodents and purpose-bred rats and mice, along with supporting services such as genetically engineered models, insourcing solutions, research animal diagnostics, and cell therapy development and production. Discovery and Safety Assessment offers in vitro and in vivo services for preclinical research, safety testing, and related studies. Manufacturing Solutions focuses on testing and contract development and manufacturing services for pharmaceuticals and consumer products. Founded in 1947 and headquartered in Wilmington, Massachusetts, the company also participates in collaborations involving cancer immunotherapy, vaccine development, and non-clinical study support.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-CRL
|
$271.28
|
-19.7% Downside
|
Overvalued
|
$346.07
|
2.4% Upside
|
Fair
|
Fair
|
0.0%
|
February 24, 2027
|
406.4x
|
5.1x
|
4.1x
|
16.331 B
|
18.836 B
|
14.8%
|
98.9%
|
4.5
|
994.4%
|